10x Genomics Q1 2024 GAAP EPS $(0.50) Misses $(0.48) Estimate, Sales $141.006M Miss $142.245M Estimate
Portfolio Pulse from Benzinga Newsdesk
10x Genomics (NASDAQ:TXG) reported Q1 2024 GAAP EPS of $(0.50), missing the $(0.48) estimate, with sales of $141.006M also missing the $142.245M estimate. This represents a 13.64% decrease in EPS and a 5.01% increase in sales year-over-year.
April 30, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
10x Genomics reported a Q1 2024 GAAP EPS of $(0.50), missing estimates by 4.17%, and sales of $141.006M, missing estimates by 0.87%. Year-over-year, EPS decreased by 13.64%, while sales increased by 5.01%.
The miss in both EPS and sales estimates for 10x Genomics in Q1 2024 is likely to negatively impact investor sentiment in the short term. Missing earnings estimates can lead to decreased investor confidence and potential sell-off, driving the stock price down. The year-over-year decrease in EPS further compounds concerns, despite the slight increase in sales.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100